Recently, new pharmacologic therapeutics targeting the glucagon-like peptide-1 receptor such as semaglutide are promising for weight loss in adults with obesity or overweight (33). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.